伴有严重皮疹的边缘区淋巴瘤：一例报告。
Marginal zone lymphoma with severe rashes: A case report.
作者信息
Bai Si-Jun, Geng Ye, Gao Yi-Nan, Zhang Cai-Xia, Mi Qian, Zhang Chen, Yang Jia-Ling, He Si-Jie, Yan Zhen-Ying, He Jian-Xia
机构信息
Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
出版信息
World J Clin Cases. 2024 Jan 26;12(3):565-574. doi: 10.12998/wjcc.v12.i3.565.
BACKGROUND
Marginal zone lymphoma (MZL) is an indolent subtype of non-Hodgkin lymphoma (NHL), which is rare clinically with severe rashes as the initial symptom.
CASE SUMMARY
This study reports a case of MZL with generalized skin rashes accompanied by pruritus and purulent discharge. First-line treatment with rituximab combined with zanubrutinib had poor effects. However, after switching to obinutuzumab combined with zanubrutinib, the case was alleviated, and the rashes disappeared.
CONCLUSION
For patients with advanced stage MZL not benefiting from type I anti-CD20 monoclonal antibody (mAb) combination therapy, switching to a type II anti-CD20 mAb combination regimen may be considered. This approach may provide a new perspective in the treatment of MZL.
背景
边缘区淋巴瘤（MZL）是非霍奇金淋巴瘤（NHL）的一种惰性亚型，临床上较为罕见，以严重皮疹为首发症状。
病例摘要
本研究报告1例伴有全身皮疹、瘙痒及脓性分泌物的MZL患者。一线使用利妥昔单抗联合泽布替尼治疗效果不佳。然而，换用奥妥珠单抗联合泽布替尼后，病情缓解，皮疹消失。
结论
对于晚期MZL患者，若I型抗CD20单克隆抗体（mAb）联合治疗无效，可考虑换用II型抗CD20 mAb联合治疗方案。该方法可能为MZL的治疗提供新的视角。
Zotero 插件